【发布时间】:2017-07-17 11:57:02
【问题描述】:
我有一个这样的csv文件,没有标题,数据格式如下:
{"article_id":724465,"title":"Addition of Aripiprazole Ups Major Depressive Disorder Remission","posting_time":1499934606065,"archive_date":"11-Jul-2018","short_desc":"Small increased likelihood of remission at 12 weeks in patients with major depressive disorder","article_type":"Journal","article_body":[{"article_desc":"WEDNESDAY, July 12, 2017 (HealthDay News) -- For patients with major depressive disorder (MDD), augmentation with aripiprazole is associated with an increased likelihood of remission, according to a study published in the July 11 issue of the Journal of the American Medical Association. \n\n Somaia Mohamed, M.D., Ph.D., from the VA Connecticut Healthcare System in West Haven, and colleagues examined the relative effectiveness and safety of three treatments for MDD in patients unresponsive to at least one antidepressant course. Patients were randomly assigned to switch to a different antidepressant, bupropion (switch group, 511 patients); augment current treatment with bupropion (augment-bupropion group, 506 patients); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, 505 patients) for 12 weeks and up to 36 weeks (acute treatment and continuous phases). \n\n The researchers found that at 12 weeks, the remission rates were 22.3, 26.9, and 28.9 percent for the switch, augment-bupropion, and augment-aripiprazole groups; the augment-aripiprazole group exceeded the switch group in remission (relative risk, 1.3). The augment-aripiprazole group had greater response compared with the switch or augment-bupropion groups (74.3 versus 62.4 percent [relative risk, 1.19] and 65.6 percent [relative risk, 1.13], respectively). There were no significant treatment differences for relapse. The bupropion groups had more anxiety (24.3, 22.5, and 16.6 percent in the switch, augment-bupropion, and augment-aripiprazole groups, respectively). \n\n Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach, the authors write. \n\n Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which provided aripiprazole for use in the study.","links":[{"link_name":"Abstract/Full Text (subscription or payment may be required)","link_url":"http://jamanetwork.com/journals/jama/article-abstract/2643308"},{"link_name":"Editorial (subscription or payment may be required)","link_url":"http://jamanetwork.com/journals/jama/article-abstract/2643294"}]}],"long_desc":"For patients with major depressive disorder, augmentation with aripiprazole is associated with an increased likelihood of remission, according to a study published in the July 11 issue of the Journal of the American Medical Association.","content_url":"http://jamanetwork.com/journals/jama/article-abstract/2643294","large_image":"https://s3-ap-southeast-1.amazonaws.com/ebiz-env-qa/content/healthday/article-images/original/24ca07f28e0db094d35038ab62df7ac5?AWSAccessKeyId=AKIAI5RP6RWRC7U5V54A&Expires=1798705806&Signature=JgcWiK1lnRnhqTDUtS%2BS9mp%2BVUI%3D","medium_image":"https://s3-ap-southeast-1.amazonaws.com/ebiz-env-qa/content/healthday/article-images/medium/24ca07f28e0db094d35038ab62df7ac5?AWSAccessKeyId=AKIAI5RP6RWRC7U5V54A&Expires=1798705806&Signature=BLZKa1YPV86ZigzxJsSx9hEchm8%3D","small_image":"https://s3-ap-southeast-1.amazonaws.com/ebiz-env-qa/content/healthday/article-images/small/24ca07f28e0db094d35038ab62df7ac5?AWSAccessKeyId=AKIAI5RP6RWRC7U5V54A&Expires=1798705806&Signature=pgnNhk12ijVV9EqmN9fRFqgatxU%3D","micro_image":"http://s3-ap-southeast-1.amazonaws.com/ebiz-env-qa/content/healthday/article-images/micro/health-day-micro.png","copyright":"http://www.healthday.com/","topics":["Depression","Prescription Drugs"],"speciality":["Acupuncture","Ayurveda","Family Medicine","Homeopathy","Nutrition","Occupational Therapy","Yoga","Other","Internal Medicine","Geriatrics","Epidemology","General Medicine","Transfusion Medicine","Nursing","Pharmacology","Psychiatry","Psychology","Sexology"]}
其中每条记录都在 csv 文件的单个单元格中,并且前面的单元格为空。
csvfile = open('Article_Data.csv', 'r')
jsonfile = open('file.json', 'w')
reader = csv.DictReader(csvfile)
for row in reader:
json.dump(row, jsonfile,indent=4)
它显示错误。所以有什么想法吗? csv 中的每条记录都是一个字典。
输出应该是这样的:
{
"article_id": 724465,
"title": "Addition of Aripiprazole Ups Major Depressive Disorder Remission",
"posting_time": 1499934606065,
"archive_date": "11-Jul-2018",
"short_desc": "Small increased likelihood of remission at 12 weeks in patients with major depressive disorder",
"article_type": "Journal",
"article_body": [
{
"article_desc": "WEDNESDAY, July 12, 2017 (HealthDay News) -- For patients with major depressive disorder (MDD), augmentation with aripiprazole is associated with an increased likelihood of remission, according to a study published in the July 11 issue of the Journal of the American Medical Association. \n\n Somaia Mohamed, M.D., Ph.D., from the VA Connecticut Healthcare System in West Haven, and colleagues examined the relative effectiveness and safety of three treatments for MDD in patients unresponsive to at least one antidepressant course. Patients were randomly assigned to switch to a different antidepressant, bupropion (switch group, 511 patients); augment current treatment with bupropion (augment-bupropion group, 506 patients); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, 505 patients) for 12 weeks and up to 36 weeks (acute treatment and continuous phases). \n\n The researchers found that at 12 weeks, the remission rates were 22.3, 26.9, and 28.9 percent for the switch, augment-bupropion, and augment-aripiprazole groups; the augment-aripiprazole group exceeded the switch group in remission (relative risk, 1.3). The augment-aripiprazole group had greater response compared with the switch or augment-bupropion groups (74.3 versus 62.4 percent [relative risk, 1.19] and 65.6 percent [relative risk, 1.13], respectively). There were no significant treatment differences for relapse. The bupropion groups had more anxiety (24.3, 22.5, and 16.6 percent in the switch, augment-bupropion, and augment-aripiprazole groups, respectively). \n\n Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach, the authors write. \n\n Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which provided aripiprazole for use in the study.",
"links": [
{
"link_name": "Abstract/Full Text (subscription or payment may be required)",
"link_url": "http://jamanetwork.com/journals/jama/article-abstract/2643308"
},
{
"link_name": "Editorial (subscription or payment may be required)",
"link_url": "http://jamanetwork.com/journals/jama/article-abstract/2643294"
}
]
}
]
}
我可以为一条记录执行此操作,但无法为 csv 中的多条记录执行此操作。
错误是,第一行被复制了n次,显示不是json格式。
【问题讨论】:
-
您的输入示例已经是有效的 json 而不是 csv 文件。
-
尝试将您的输入减少到可管理的内容。不要向我们倾倒数百个字符。你可以用几十个字符重现问题。
-
您的示例数据是否全部在 CSV 的一个单元格中,并且前面的单元格为空?并且有很多行完全相同?
-
你得到什么错误?
-
@SuperShoot 是的,它是单一的,前面是空的。所有的行都是这样,每条记录在该行的第一列。